Back to Trades
Sell4
HALOZYME THERAPEUTICS, INC.
HALO
Total Value
$4.8M
Net $3.8M sold
Sales
$3.8M
6 transactions
Company Information
- Company Name
- HALOZYME THERAPEUTICS, INC.
- Ticker Symbol
- HALO
- CIK
- 0001159036
Insider Information
- Name
- Torley Helen
- Role
- Insider
- Location
- SAN DIEGO, CA
Filing Details
- Filing Date
- Aug 13, 2025
- Transaction Date
- Aug 11, 2025
- Accession Number
- 0001415889-25-021681
- Form Type
- 4
- Net Trading Amount
- -$3.8M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Aug 11, 2025 | Common Stock | 20,000 | $8.11 | Exercise | $162.2K |
| Aug 11, 2025 | Common Stock | 18,717 | $63.01 | Sale | $1.2M |
| Aug 11, 2025 | Common Stock | 1,283 | $63.60 | Sale | $81.6K |
| Aug 12, 2025 | Common Stock | 20,000 | $8.11 | Exercise | $162.2K |
| Aug 12, 2025 | Common Stock | 13,042 | $63.24 | Sale | $824.8K |
| Aug 12, 2025 | Common Stock | 6,958 | $64.00 | Sale | $445.3K |
| Aug 13, 2025 | Common Stock | 20,000 | $8.11 | Exercise | $162.2K |
| Aug 13, 2025 | Common Stock | 14,948 | $64.14 | Sale | $958.8K |
| Aug 13, 2025 | Common Stock | 5,052 | $64.83 | Sale | $327.5K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Aug 11, 2025 | Derivative | 20,000 | $8.11 | Exercise | $162.2K |
| Aug 12, 2025 | Derivative | 20,000 | $8.11 | Exercise | $162.2K |
| Aug 13, 2025 | Derivative | 20,000 | $8.11 | Exercise | $162.2K |
Footnotes
- (F1)The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.
- (F2)Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.54 to $63.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F3)Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.54 to $63.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F4)Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.68 to $63.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F5)Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.745 to $64.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F6)Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.70 to $64.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F7)Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.70 to $64.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F8)Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.